Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus
| العنوان: | Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus |
|---|---|
| المؤلفون: | Daniela Lamers, Ulrik Mouritzen, Ulrike Hövelmann, Tim Heise, Minna Braendholt Olsen, Birgit Kronshage |
| المصدر: | Diabetes, Obesity & Metabolism |
| بيانات النشر: | Blackwell Publishing Ltd, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, Pancreas, Artificial, medicine.medical_specialty, Adolescent, type 1 diabetes, Endocrinology, Diabetes and Metabolism, Injections, Subcutaneous, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Glucagon, Artificial pancreas, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Insulin Infusion Systems, Pharmacokinetics, Double-Blind Method, Internal medicine, Internal Medicine, medicine, pharmacodynamics, Potency, Humans, Insulin, Type 1 diabetes, Plasma glucose, Cross-Over Studies, Dose-Response Relationship, Drug, business.industry, Original Articles, Middle Aged, medicine.disease, Hypoglycemia, Diabetes Mellitus, Type 1, Pharmacodynamics, Area Under Curve, Vomiting, Original Article, Female, medicine.symptom, business, pharmacokinetics, hypoglycaemia |
| الوصف: | AIM To characterize the pharmacokinetic and pharmacodynamic properties of dasiglucagon, a novel, stable and liquid formulated glucagon analogue, during hypoglycaemic and euglycaemic conditions in adult patients with type 1 diabetes mellitus. RESEARCH DESIGN AND METHODS In this randomized double-blind trial, 17 patients received four single subcutaneous doses (0.03, 0.08, 0.2 and 0.6 mg) of dasiglucagon (4 mg/mL formulation) under euglycaemic (plasma glucose [PG] 5.6 mmol/L [100 mg/dL]) or hypoglycaemic (PG 3.1-3.7 mmol/L [56-66 mg/dL]) conditions. For comparison, three doses (0.03, 0.08 and 0.2 mg) of a commercial glucagon formulation (Eli Lilly) were investigated at euglycaemia. RESULTS Dasiglucagon led to a dose-dependent and rapid increase in PG levels across all doses tested (mean increases 30 minutes post-dosing of 2.2 to 4.4 mmol/L [39-80 mg/dL] from euglycaemia and 1.3 to 5.2 mmol/L [24-94 mg/dL] from hypoglycaemia), which was higher than the rises elicited by similar doses of commercial glucagon (1.7-3.9 mmol/L [30-71 mg/dL]). The median time (range) to an increase in PG of >1.1 mmol/L (20 mg/dL) was |
| اللغة: | English |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f21c5aeb2d9443e70883f8020af9b91Test http://europepmc.org/articles/PMC6587565Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4f21c5aeb2d9443e70883f8020af9b91 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|